PP405 is ineffective for miniaturized, fibrosed hairfollicles in androgenetic alopecia. AMP303 may activate hairfollicle stem cells, but minoxidil and finasteride are still the main treatments.
Hair loss is linked to scalp fibrosis and tension, which result from chronic mechanical stress and androgenic signaling. Treatments include blocking androgens with finasteride, promoting hair growth with topical minoxidil, and improving scalp mobility through exercises.
Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.
The conversation is about a 17-year-old experiencing severe hair thinning and the advice given is to see a dermatologist or doctor to check for underlying health issues or to start treatment early if it's male pattern baldness.
Creatine may cause hair loss in some individuals, especially those on finasteride, despite no scientific link. Personal experiences suggest individual sensitivity to DHT could be a factor.
Hair loss treatments, including minoxidil, dermarolling, finasteride, dutasteride, hair transplants, hair systems, and shaving the head. The conversation covers various opinions on these treatments and mentions possible side effects as well as alternatives like wigs, vitamins, and lifestyle changes. The post expresses disappointment that there has been no major breakthrough in the field of hair loss treatments despite decades of research.
After 11 years on Finasteride, a user's hair is thinning again, suggesting hair may become more sensitive to DHT with age. They plan to introduce Dutasteride once a week, as they cannot tolerate Minoxidil.
A user with aggressive male pattern baldness found that topical melatonin significantly reduced their hair shedding to 1 or 2 hairs per day and noticed some thickening of side hair. They tried many treatments like finasteride and minoxidil with little success, but topical melatonin showed immediate results in reducing hair loss.
PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.
Hair loss treatments, specifically the use of finasteride, microneedling and potentially oral minoxidil. People discussed their experiences with finasteride, its effects on sexual behaviors, as well as potential solutions such as tadalafil or using other growth factor signal peptides for hope in curing male pattern baldness.
DHT promotes beard growth but causes scalp hair loss due to inflammation and fibrosis. Treatments like finasteride and minoxidil help with hormonal signals and blood flow but don't address underlying inflammation.
The user reported significant hair improvement over 15 months using dutasteride, minoxidil (oral and topical), RU58841, ketoconazole, and microneedling. They are considering a hair transplant in 4-6 months.
A 20-year-old is experiencing hair thinning and seeks advice on starting treatment and regrowing hair. They are considering using Minoxidil, finasteride, or RU58841.
Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.
The original poster believes shaving his head made him more attractive to a specific group of women, despite being less attractive overall. The conversation includes various opinions on attractiveness, with some agreeing that being bald can work for certain men, while others suggest maintaining hair is generally more appealing.
The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.
DHT is important for sexual function and mood, but finasteride and dutasteride can reduce DHT, causing side effects like reduced libido and erectile dysfunction. These treatments are effective for hair loss, but their impact on DHT leads to debate.
Baldness is not an evolutionary disadvantage because it occurs after reproductive age. Treatments like Minoxidil and Finasteride are used for androgenetic alopecia but don't address the root cause.
The user experienced significant hair regrowth and increased density after six months of using oral minoxidil and finasteride chewables, despite going through a secondary shedding phase. The only side effect mentioned was restlessness, and the user feels healthier overall.
The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hairfollicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.
Hair loss is linked to the loss of stem cells in hairfollicles, and potential treatments include gene editing and microneedling. Discussions also mention using Minoxidil, finasteride, and dermarolling to improve hair growth.
PP405 is a new hair loss treatment targeting dormant hairfollicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
PP405 shows promise in activating dormant hairfollicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.
PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hairfollicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hairfollicles. Further research and long-term follow-up are needed to confirm these findings.
PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.
